Home Stock

Stock Research: Ajanta Pharma

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Ajanta Pharma

NSI:AJANTPHARM INE031B01049
47
  • Value
    26
  • Growth
    77
  • Safety
    Safety
    84
  • Combined
    70
  • Sentiment
    38
  • 360° View
    360° View
    47
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Ajanta Pharma Limited is an India-based specialty pharmaceutical company providing a comprehensive range of branded generic products. It operates in therapeutic segments like cardiology, anti-diabetes, ophthalmology, dermatology, antibiotics, anti-malarial, pain, respiratory, gynecology, pediatric, and general health, with businesses in the United States generics and institutional segments in Africa. It is focused on branded generic businesses across India, Asia, and Africa. In the last fiscal year, the company had a market cap of $4076 millions, profits of $412 millions, revenue of $544 millions, and 9628 employees.

more

ANALYSIS: With an Obermatt 360° View of 47 (better than 47% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ajanta Pharma are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Ajanta Pharma. The consolidated Growth Rank has a good rank of 77, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 77% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 84 which means that the company has a financing structure that is safer than 84% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 26 which means that the share price of Ajanta Pharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 74% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 38, which means that professional investors are more pessimistic about the stock than for 62% of alternative investment opportunities. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Safety
Country India
Industry Pharmaceuticals
Size Large
Website ajantapharma.com
Index
Ajanta Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 11-Nov-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
26 25 37 49
Growth
77 69 89 49
Safety
Safety
84 84 82 69
Sentiment
38 33 92 41
360° View
360° View
47 54 96 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
47 33 91 3
Opinions Change
21 7 50 50
Pro Holdings
n/a 34 80 100
Market Pulse
75 76 58 31
Sentiment
38 33 92 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
26 25 37 49
Growth
77 69 89 49
Safety Safety
84 84 82 69
Combined
70 78 93 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
16 23 44 36
Price vs. Earnings (P/E)
28 32 49 53
Price vs. Book (P/B)
13 23 38 44
Dividend Yield
73 37 29 56
Value
26 25 37 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
69 76 63 59
Profit Growth
45 43 76 28
Capital Growth
60 28 46 39
Stock Returns
80 93 93 71
Growth
77 69 89 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
77 90 88 92
Refinancing
60 36 38 26
Liquidity
82 82 78 76
Safety Safety
84 84 82 69

Similar Stocks

Discover high‑ranked alternatives to Ajanta Pharma and broaden your portfolio horizons.

Aurobindo Pharma

NSI:AUROPHARMA
Country: India
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Gail

NSI:GAIL
Country: India
Industry: Gas Utilities
Size: X-Large
Full Stock Analysis

Apollo Tyres

NSI:APOLLOTYRE
Country: India
Industry: Tires & Rubber
Size: Large
Full Stock Analysis

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews